April 9, 2021 PAO-04-22-R221-11
At another stop on the Road to 2021 road trip, Calum Stevens, Commercial Director for BDD Pharma, discusses business development challenges in the wake of COVID-19 and BDD’s investment in OSD technology.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
BDD combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success.
Prove your product claims with BDD Scintigraphy, best in class scintigraphic clinical trials.
A unique patented time release technology, OralogiK™ provides unrivalled control of drug release at the right place and the right time to achieve a superior and clinically effective drug delivery profile.
BDD SWIFT for rapid clinical development. SWIFT accelerates evaluation and optimisation of product performance using in vivo clinical data to direct formulation design in real time. SWIFT studies enable you to make decisions on formulation changes based on emerging clinical data. This integration of formulation development, GMP manufacturing and clinical testing activities can reduce the time from initial prototype development to clinical results to just 6 months.